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Positron emission tomography (PET) is unique in that it allows quantification of biochemical processes
in vivo, but difficulties with preparing suitably labelled radiotracers limit its scientific and diagnostic
applications. Aromatic [
18F]fluorination of drug-like small molecules is particularly challenging as their
functional group compositions often impair the labelling efficiency. Herein, we report a new strategy for
incorporation of
18F into highly functionalized aromatic compounds using sulfonium salts as leaving
groups. The method is compatible with pharmacologically relevant functional groups, including aliphatic
amines and basic heterocycles. Activated substrates react with [
18F]fluoride at room temperature, and with
heating the reaction proceeds in the presence of hydrogen bond donors. Furthermore, the use of electron
rich spectator ligands allows efficient and regioselective [
18F]fluorination of non-activated aromatic
moieties. The method provides a broadly applicable route for
18F labelling of biologically active small
molecules, and offers immediate practical benefits for drug discovery and imaging with PET.
P
ositronemissiontomography(PET)isahighlysensitivemedicalimagingtechniquethatreliesontheuseof
radioactive tracers for quantification of biochemical processes in vivo. While several radionuclides are
suitable for PET, fluorine-18 (half-life 110 min) is by far the most widely used due to its near ideal decay
properties for imaging, small atomic size and ability to form stable C-F bonds. Fluorine-18 is typically produced
by bombardment of
18O enriched water ([
18O]H2O) with a beam of protons, which provides [
18F]fluoride in high
yield and with high specific activity through the
18O(p,n)
18F nuclear reaction. However, labelling of drug-like
small molecules is challenging as there are few positions available for incorporation of
18F, and the presence of
hydrogen bond donating and accepting groups often impairs the reactivity. With the restrains imposed by the
half-life of
18F, which makes multi-step radiochemical routes impractical, and the limitations of protection-
deprotection strategies, the drug-like chemical space that is accessible for labelling remains marginal. It is
therefore a pressing need to develop new strategies for incorporation of
18F that combine broad substrate scope
with high functional group tolerance, in particular to basic aliphatic moieties, in order to expand the arsenal of
PET tracers that can be made available for clinical applications.
Aromatic [
18F]fluorination is attractive as the steric and electronic effects of substituting a hydrogen atom with
fluorine are subtle, yet it can improve the metabolic stability of the parent compound
1,2. Nucleophilic aromatic
substitution of nitro, trimethylammonium and halide leaving groups with [
18F]fluoride is the most widely used
approach. However, the reaction is limited to activated substrates, harsh conditions are typically required, and
purification of the resulting tracers can be difficult
3,4. Extensive efforts have been made to overcome these limitations,
and recent progress in fluorine chemistry has greatly expanded the repertoire of reactions available for
[
18F]fluorination
5.Thisincludestheuseofalternativeleavinggroupssuchasaromaticsulfoniumsaltsandsulfoxides
6,7,
as well as transition metal and hypervalent iodine complexes
8. The development of palladium mediated fluorination
wasamajorconceptualbreakthroughasitallowslabellingofawiderangeofaromaticmoieties,includingelectronrich
arenes, with [
18F]fluoride
9,10. Yet, applications of the method have been hampered by the reliance on air sensitive
palladium complexes that are demanding to synthesize, and that must be prepared freshly before labelling. Arylnickel
complexes were reported to overcome some of these shortcomings, but have only been demonstrated to work with
analytical levels of [
18F]fluoride (,20 MBq)
11. Recently, pinacol derived aryl boronate esters were shown to undergo
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18Fl a b e l l i n gi nt h ep r e s e n c eo fac o m m e r c i a l l ya v a i l a b l ec o p p e r
complex (Cu(OTf)2(py)4,),whichmakesthisapproachmoreaccessible,
althoughthehighconcentrationofprecursorsusedinthereactionspose
a number of practical challenges
12. Following two decades of optimisa-
tion, several hypervalent iodine complexes have emerged as attractive
alternatives to transition metal based labelling methods as they allow
[
18F]fluorination of a broad scope of aromatic moieties using conven-
tional reaction conditions
13–15. Despite these remarkable developments,
hypervalent iodine, as well as transition metal complexes, have so far
only been applied to ‘late-stage’ [
18F]fluorination of fully protected
substrates, such as amino acids, or compounds that lack reactive
functional groups, for instance [
18F]fluoroestrone and the TSPO ligand
[
18F]DAA1106
5. Direct aromatic [
18F]fluorination of non-activated
compounds containing aliphatic amines or other similarly basic
moieties, has yet to be demonstrated. This is a fundamental limitation
for applications to PET, as the majority of drugs contain basic moieties,
very frequently tertiary aliphatic amines, which cannot be masked with
protection-deprotection strategies
16.
Recently, we aimed to design
18Fl a b e l l e dt r a c e r sf o ri m a g i n go f
transportmechanismsattheblood-brainbarrier,usingfragmentsfrom
archetypicalcentrally-actingdrugssuchashaloperidol,terfenadineand
ritanserin (Figure 1). Due to the poor compatibility of the available
labelling methods with the structural properties of these drugs, in par-
ticular the shared piperidine scaffold, sulfonium salts were explored as
alternative leaving groups for [
18F]fluorination. Herein, we report the
developmentandapplicationsofahighlyefficientandversatilemethod
for aromatic labelling of drug-like molecules based on the reaction of
functionalized triarylsulfonium salts with [
18F]fluoride.
Results
Synthesis of functionalized sulfonium salts as labelling
precursors. Triarylsulfonium salts have been reported to allow
highly efficient labelling of [
18F]fluorobenzene and activated aryls,
but as few methods are available to prepare the required precursors,
practical examples have so far been limited to simple aromatic
systems bearing unreactive functional groups
7. In our case,
employment of a ketone building block (cf. Figure 1) precluded the
use of organometallic reagents
17–19, and attempted reaction of the
thioether 1a with diaryliodonium triflate under copper(II) cata-
lysis
20 failed to provide the desired sulfonium salt 1b (Figure 2). As
aliphatic amines coordinate strongly with copper(II) ions, and the
resulting complexes can undergo an intramolecular redox reaction
to give copper(I)
21, we attempted to mask the piperidine moiety
by protonation with trifluoromethanesulfonic acid (TFSA). Grati-
fyingly, the corresponding TFSA salt of 1a reacted cleanly with
diaryliodonium triflate (125uC, 1 h) to give the desired sulfonium
salt 1b in 60% yield (Figure 2). The compound proved highly stable
and could readily be purified by column chromatography on silica.
To enable labelling, the base was liberated after purification by
extraction with aqueous sodium hydroxide (2 M).
Radiolabelling of functionalized sulfonium salts. Screening of
solvents and bases commonly used for nucleophilic substitution
reactions with [
18F]fluoride revealed dimethyl sulfoxide (DMSO)
and potassium bicarbonate to be optimal for labelling. Under these
conditions (5 mg precursor, 0.5 ml DMSO, 110uC, 15 min), the
sulfonium salt 1b reacted with [
18F]fluoride to give [
18F]1c in 61%
radiochemical yield (RCY) as determined by radio-HPLC
(cf. Figure 2). The reaction also proceeded at 50uC, although in lower
yield (Supporting information, Figure S14). To gain a better
understanding of the impact of the temperature on the reaction,
we used benzophenone 2b as a model compound. For this
substrate, labelling proceeded with comparable efficiency at 50 and
110uC, and afforded [
18F]2c in 61% and 68% RCY, respectively.
Remarkably, the reaction also took place at room temperature to
give [
18F]2c in 31% RCY. The high reactivity prompted us to
explore labelling in the presence of hydrogen bond donating
groups with the aim to circumvent the need for protection-
deprotection strategies. Indeed, the primary alcohol 3b reacted
smoothly with [
18F]fluoride at 110uC to give [
18F]3c in 33% RCY.
Similarly, the secondary amine [
18F]4c was obtained in 31% RCY
using the sulfonium salt 4b as the precursor. While nucleophilic
[
18F]fluorination has been reported to occur in the presence of
unprotected alcohols, this is the first demonstration that labelling
of small molecules with [
18F]fluoride can be achieved in useful RCY
in the presence of secondary amines and primary alcohols
5,8,22.
Encouraged by the unique reactivity of the sulfonium salts, we
investigated the possibility of labelling drug-like target compounds
directly (cf. Figure 1). Reaction of the sulfonium salt 8b, decorated
with an electron neutral piperidin-4-ylidene moiety, with
[
18F]fluoride resulted in formation of [
18F]fluorobenzene as the
major radiochemical product (28% RCY), but nevertheless
Figure 1 | Approach to labelling of drug-like molecules. (a) Structures of
archetypical centrally-acting drugs. (b) Retrosynthetic approach to
[
18F]fluorinated aryl ketone building blocks.
Figure 2 | Synthesis of the triarylsulfonium salts 1b–4b and the
corresponding radioactive products [
18F]1c–4c. (a) Reagents and
conditions: (i) TFSA (entries 1,3,4), diphenyliodonium triflate, Cu(II)
benzoate, chlorobenzene, 1 h, 125uC; (ii) [
18F]F2, KHCO3,K 222, DMSO,
15 min. (b) Structures and yields: (i) isolated as triarylsulfonium triflate
salts; non-optimized yields of a single reaction; (ii) analytical (and
decay-corrected isolated) radiochemical yields (RCY); experiments were
performed in triplicate (6SD).
www.nature.com/scientificreports
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18F]8c in 21% RCY (Figure 3). In
order to improve the regioselectivity of the reaction we opted to
design triarylsulfonium salts with electron-rich aromatic ligands.
In accordance with published results
7, and as demonstrated by
the clean reaction of the asymmetric sulfonium salt 5b to
[
18F]2-fluorobenzoate (80% RCY), [
18F]fluoride preferentially
reacts at the most electron deficient of the three sulfonium-
substituted carbons (Figure 4b, Entry 1). Further evaluation of
sulfonium salts bearing two anisole groups (6b and 7b) showed
identical labelling efficiency for ortho- and para-methoxy
substituents, with formation of [
18F]fluorobenzene in 40% RCY.
For practical reasons, and to aid characterization by NMR, para-
methoxy residues were chosen as spectator ligands, and the
sulfonium salt 9b was prepared accordingly. In contrast to the
parent compound 8b,t h epara-methoxy functionalized precursor 9b
reacted regioselectively and provided [
18F]8c with increased RCY
(33%) (Figure 3). To the best of our knowledge, this is the first
example of direct aromatic [
18F]fluorination of a non-activated
substrate in the presence of a non-protected aliphatic amine.
Applications to PET. With this new labelling strategy in hand we
prepared several derivatives of [
18F]8c, and following biological
evaluation, [
18F]10d was identified as a lead compound (details to
be reported elsewhere). The tracer exhibits an exceptionally high
brain uptake with peak brain-to-blood ratios approaching 10: 1 in
rodents (Figure 5). However, the lack of an activating electron
withdrawing group in compound [
18F]10d, and the presence of the
primaryalcohol,proveddetrimentaltothelabellingefficiency(,5%
RCY). The alcohol was therefore protected as an acetate, and
treatment of the corresponding sulfonium salt precursor 10b with
[
18F]fluoride, followed by ester hydrolysis, afforded the target
compound in 9% decay-corrected isolated RCY (Figure 4b, Entry
2). The total synthesis time was 120 min, including formulation.
When starting with 2 GBq, tracer [
18F]10d was obtained with a
specific activity of 4.0 GBq/mmol.
The scope of the labelling reaction was further evaluated using
heteroaromatic compounds (Figure 4b, Entries 3–6). The highly
activated diphenyl(pyridin-2-yl)sulfonium salt 11b reacted readily
with [
18F]fluoride at room temperature to give [
18F]11c in 68% ana-
lyticalRCY,andwithmoderateheating(50uC)theRCYreached80%
(cf. Supporting information, Figure S14). To demonstrate practical
applicability,thesulfoniumsalt12bwasusedtopreparethenicotinic
acetylcholine receptor ligand [
18F]12d as a representative example of
a class of 2-fluoropyridine containing radiotracers, such as
[
18F]flubatine or [
18F]nifene, that currently are in use for imaging
of neurodegenerative diseases
23,24. In this instance, the high polarity
of the corresponding deprotected sulfonium salt of 12b made puri-
fication difficult, and the Boc group was therefore left intact for the
labelling reaction. Treatment of 12b with [
18F]fluoride, and sub-
sequent deprotection, afforded [
18F]12d in 51% decay-corrected iso-
lated RCY. Imidazole is an important motif for PET chemistry as it
mediates binding to an array of enzymes and receptors. As an
example of this class of compounds, we labelled the benzylic 1H-
imidazole [
18F]13c (31% RCY), a structural analogue of
[
11C]metomidate, which has shown promise as a tracer for imaging
of adrenal lesions
25. Finally, we prepared the iminodihydroquinoline
[
18F]14c,a[
18F]fluorinated analogue of the potassium channel
blocker CP-339,818
26, with the goal to characterise the pharmacoki-
netic properties of the compound by dynamic PET imaging. Under
optimized reaction conditions (120uC,15 min)the target compound
was obtained in 30% decay-corrected isolated RCY. Intriguingly,
the pharmacokinetic profile of [
18F]14c, as determined by PET
(Figure 5), closely resembled that of a previously reported
[
125I]iodinated derivative
27. The high labelling efficiency achieved
fortheelectronneutralbenzylicgroupopensuptheprospectofusing
18F as a scouting radionuclide to characterize the pharmacokinetic
properties of lead compounds during the early stages of drug
development. The omnipresence of benzylic groups, and other elec-
tron neutral aromatic and heteroaromatic moieties, in drug-like
small molecules makes this a widely applicable labelling strategy.
Discussion
We have developed practical synthetic protocols that allow
sulfonium salts to be incorporated as leaving groups for
[
18F]fluorination of drug-like molecules. Importantly, the method
is fully compatible with Lewis bases, including aliphatic amines,
imines and basic heterocycles, as well as other common functional
groups, such as alcohols, aldehydes, ketones, and esters. However,
the synthetic route is not without limitations. Diaryliodonium salts
can react with a number of nucleophiles, and competing arylation of
heteroatoms can prevent sulfonium salt formation
28,29. N-arylation
can also give rise to permanently charged side products that make
purificationofthetargetcompoundsimpractical.Whileprotonation
of basic functional groups conveniently masks nucleophilic nitro-
gens,thisisnotalwaysafeasiblestrategy,andforconjugatedsystems,
protonation can abolish the reactivity of the diaryl thioether.
Triarylsulfonium salts have high thermal and chemical stability,
yet they exhibit a remarkable reactivity with fluoride. Conveniently,
[
18F]fluorination can be carried out under conventional radiochemi-
calconditionsthatareroutinely usedforGMPcompliantautomated
tracerpreparation.Labellingofactivatedsubstratesproceedsatroom
temperature, and with heating the reaction occurs in the presence of
unprotected alcoholsandsecondaryamines.Furthermore, theuseof
electron rich spectator ligands allows regioselective [
18F]fluorination
of non-activated aromatic moieties, including electron neutral
benzylicgroups.Importantly, Lewisbases,includingtertiaryamines,
are well tolerated in the reaction. However, hydrogen bond donors
reduce the labelling efficiency, and in the case of non-activated sub-
strates, they need to be masked with protecting groups. Nonetheless,
the ability to label non-activated aromatic groups with
18F in the
presence of basic moieties provides, for the first time, a method that
is broadly applicable to drug-like compounds, and hence opens up
extensive pharmacological space for the design of small molecule
PET tracers.
In conclusion, we have developed a novel strategy for aromatic
[
18F]fluorination of drug-like molecules using sulfonium salts as
leaving groups. The method allows efficient labelling of electron
Figure 3 | Labelling of [
18F]8c. (a) Reagents and conditions: (i) [
18F]F2,
KHCO3,K 222, DMSO, 15 min, 110uC; analytical (and decay-corrected
isolated) radiochemical yields; experiments were performed in triplicates
(6SD). (b) Radio-HPLC chromatograms of the reaction mixture when
using 8b (dotted line) or 9b (full line) as labelling precursor.
www.nature.com/scientificreports
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tional groups and heterocyclic moieties. This provides, for the first
time, a broadly applicable and practical method for aromatic
[
18F]fluorination of drug-like molecules and offers immediate bene-
fitsforapplicationstodrugdiscoveryandmedicalimagingwithPET.
Methods
Synthetic procedures and full analytical characterisation of all labelling precursors,
non-labelled reference compounds and [
18F]labelled compounds can be found in the
supplementary information.
Synthesis of triarylsulfonium salts – example 1b. To a solution of the thioether
1a (100 mg, 0.24 mmol 5 1 equiv.) in chlorobenzene (1 ml) were added TFSA
(1 equiv.), diphenyliodonium triflate (1 equiv.) and copper(II) benzoate hydrate (5%)
and the mixture was heated at125uC for 1 h. After cooling, the resulting brown oil was
washed with diethyl ether (3 3 5 ml). The product was purified by column
chromatography (DCM: methanol5 10:0 to9:1). Theisolatedproductwas dissolved
inDCM(5 ml)andwashedwithaqueoussodiumhydroxide(2M;5 ml)andasaturated
solution of sodium triflate (5 ml). The organic phase was dried (magnesium sulfate),
filtered and concentrated to give 1b as a colourless oil (90 mg, 60%).
Labelling of triarylsulfonium salts – example [
18F]1c. [
18F]Fluoride in [
18O]H2O
(50–200 MBq) was trapped on a Sep-PakH QMA cartridge and released with a
solution (0.5 ml) of Kryptofix 222 (30 mM) and potassium bicarbonate (30 mM) in
acetonitrile: water (85: 15). The solvent was removed by heating at 90uC under a
stream of nitrogen, and [
18F]fluoride was dried by azeotropic distillation with
acetonitrile (2 3 0.5 ml; 90uC). The reaction vial was capped, a solution of the
sulfoniumsalt1b(5 mg)inDMSO(0.5 ml)wasadded,andthemixturewasstirredat
110uC for 15 min. After cooling, water (1.5 ml) was added and the reaction mixture
was purified by HPLC to give [
18F]1c in 39 62% decay-corrected isolated RCY.
Analytical RCYs (61 64%) were measured with radio-HPLC.
Determination of RCY and specific activity (cf. Figures 2 and 4). The entire
quenched reaction mixture was used to determine analytical and decay-corrected
isolated RCY, and no corrections were made to account for losses during the
Figure 4 | Synthesis of the functionalized triarylsulfonium salts 5b–14b and labelling of the corresponding radioactive products [
18F]5c–14c.
(a) Reagents and conditions: (i) TFSA (entries 2,5,6), diaryliodonium triflate, Cu(II) benzoate, chlorobenzene, 1–2 h, 125uC; (ii) [
18F]F2, KHCO3,
K222, DMSO, 15 min. (b) Structures and yields: (i) isolated as triflate salts; non-optimized yields of a single reaction; (ii) analytical (and decay-corrected
isolated) radiochemical yields (RCY); experiments were performed in triplicate (6SD); (iii) analytical RCY of a single experiment; (iv) RCY after two
steps.
Figure 5 | Nano-PET/CT imaging in mice. (a) Peak brain uptake of the
PET tracer [
18F]10d.( b) Pharmacokinetic profile of the drug candidate
[
18F]14c.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9941 | DOI: 10.1038/srep09941 4preparative procedure. Decay-corrected isolated RCY were calculated by relating the
amount of isolated radioactive product to the initial amount of [
18F]fluoride in
[
18O]H2O.AnalyticalRCYweredeterminedbyintegratingtheareaunderthecurvein
thepreparativeradio-HPLCchromatogram.Thespecificactivitywascalculatedfrom
thetotalareaunderthecurveintheUVchromatogramthatoverlappedwiththepeak
of the radioactive target compound.
Animal experiments. Animal experiments were performed in accordance with the
United Kingdom Home Office’s Animals (Scientific Procedures) Act 1986 and were
approved by the University College London Animal Ethics Committee.
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